pyrrolitinib
Small moleculeexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2020 (NCT04785729)
Timeline
Indications
Studied for
Mechanism of action
EGFR inhibitor
ERBB4 inhibitor
ERBB3 inhibitor
ERBB2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05918328 | Phase 2 | May 3, 2023 | Henan Medical University |
| NCT06470347 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2022 | Zunyi Medical College |
| NCT05353361 | Phase 2 | May 15, 2022 | Hengrui Therapeutics, Inc. |
| NCT04785729 | Phase 2 | Dec 31, 2020 | Sun Yat-Sen University |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Henan Medical University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Hengrui Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2022 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Zunyi Medical College | Academic/Hospital | 1 | 1 | 1 | 2022 |
4 organizations
Page 1 / 1